NCT05440227View on ClinicalTrials.gov

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Cancer-related Fatigue
Interventions
DRUG

PG2 Lyo. Injection 500mg

PG2 Lyo. Injection 500mg (reconstituted with 0.9% normal saline 500ml) will be administered weekly for 8 weeks.

DRUG

Placebo 0.9% normal saline

0.9% normal saline 500ml will be administered weekly for 8 weeks.

Trial Locations (1)

Unknown

RECRUITING

National Taiwan University Hospital, Taipei

Sponsors
All Listed Sponsors
lead

PhytoHealth Corporation

INDUSTRY